Medical Marijuana For Staph; Other Ailments (GFON)
Posted Jul 11 2010 12:00am
Also from April, 2009…
Medical Marijuana reduces the spread of drug-resistant bacteria, including methicillin-resistant Staphyloccus aureus (MRSA). Just one more use for medical marijuana…
From BioHealth Investor – Biotech and Medical Business Blog – April 23, 2009
It is hard to imagine that there are now two medical-related marijuana companies that are public stocks. But that is the new world for you. Cannabis Science, Inc. (OTCBB: GFON) has a report on the current state of research into the use of natural plant cannabinoids to reduce the spread of drug-resistant bacteria, including methicillin-resistant Staphyloccus aureus (MRSA), and the prospects for development of topical whole-cannabis treatments.
The company noted a Journal of the American Medical Association and a Center for Disease Control in 2007 report, showing that MRSA is responsible for more than 18,500 hospital-stay related deaths each year, and increased direct healthcare costs of as much as $9.7 billion.
Dr. Melamede, chief scientist and director at Cannabis Science, Inc., noted that research into use of whole cannabis extracts and multi-cannabinoid compounds has provided the scientific rationale for medical marijuana’s efficacy in treating some of the most troubling diseases mankind now faces. What is interesting is that the reference was made to infectious diseases such as the flu and HIV, autoimmune diseases such as ALS, multiple sclerosis, arthritis, diabetes, neurological conditions such as Alzheimer’s, stroke and brain injury, and numerous forms of cancer.